Silence Therapeutics PLC Grant of Employee Options (6452W)
April 27 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 6452W
Silence Therapeutics PLC
27 April 2021
Grant of Employee Options
27(th) April 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that it has granted
160,000 options under the Silence Therapeutics plc 2018 Employee
Long Term Incentive Plan to Giles Campion, M.D., Executive Director
of the Company. The options will have a strike price of GBP5.50,
the mid-market closing price on AIM on April 22, 2021.
The notification below is made in accordance with the
requirements of the EU Market Abuse Regulation as it forms part of
UK law by virtue of the European Union (Withdrawal) Act 2018.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Giles Campion, M.D.
--------------------------- ------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------
a) Position / status Executive Director
--------------------------- ------------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- ------------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of Ordinary Shares of nominal value 5 pence
the financial instrument, each in the capital of Silence Therapeutics
type of instrument plc
Identification
code
ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- ------------------------------------------------
b) Nature of the transaction Grant of options under the Silence Therapeutics
plc 2018 Employee Long Term Incentive
Plan
--------------------------- ------------------------------------------------
c) Prices(a) and volume(s) Price Volume
Nil 160,000
--------
--------------------------- ------------------------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
--------------------------- ------------------------------------------------
e) Date of the transaction 22 April 2021
--------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ------------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDQLFLFZLZBBD
(END) Dow Jones Newswires
April 27, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024
